新冠病毒疫苗的未来如何？

Whither COVID-19 vaccines?

机构信息

Nature Biotechnology, .

出版信息

Nat Biotechnol. 2020 Oct;38(10):1132-1145. doi: 10.1038/s41587-020-0697-7.

DOI:10.1038/s41587-020-0697-7

PMID:32989315

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7520880/

Abstract

convenes a group of experts to provide their insights into SARS-CoV-2 vaccines in development.

摘要

召集了一组专家，就正在开发的 SARS-CoV-2 疫苗提供他们的见解。

相似文献

Whither COVID-19 vaccines?

Nat Biotechnol. 2020 Oct;38(10):1132-1145. doi: 10.1038/s41587-020-0697-7.

Approaches and Challenges in SARS-CoV-2 Vaccine Development.

Cell Host Microbe. 2020 Sep 9;28(3):364-370. doi: 10.1016/j.chom.2020.08.002. Epub 2020 Aug 10.

COVID-19 herd immunity: where are we?

Nat Rev Immunol. 2020 Oct;20(10):583-584. doi: 10.1038/s41577-020-00451-5.

DNA vaccine protection against SARS-CoV-2 in rhesus macaques.

Science. 2020 Aug 14;369(6505):806-811. doi: 10.1126/science.abc6284. Epub 2020 May 20.

Impact of glycoscience in fighting Covid-19.

Glycoconj J. 2020 Aug;37(4):511-512. doi: 10.1007/s10719-020-09929-9.

Developing Covid-19 Vaccines at Pandemic Speed.

N Engl J Med. 2020 May 21;382(21):1969-1973. doi: 10.1056/NEJMp2005630. Epub 2020 Mar 30.

COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.

Comput Biol Med. 2020 Jun;121:103749. doi: 10.1016/j.compbiomed.2020.103749. Epub 2020 Apr 11.

Fast-and-fit vaccines.

Nat Biomed Eng. 2020 Aug;4(8):757-758. doi: 10.1038/s41551-020-00605-9.

The COVID-19 vaccine development landscape.

Nat Rev Drug Discov. 2020 May;19(5):305-306. doi: 10.1038/d41573-020-00073-5.

Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice.

Cell Host Microbe. 2020 Sep 9;28(3):465-474.e4. doi: 10.1016/j.chom.2020.07.018. Epub 2020 Jul 30.

引用本文的文献

A Spike-Based mRNA Vaccine Encapsulated in Phospholipid 1,2-Dioleoyl-sn-Glycero-3-PhosphoEthanolamine Containing Lipid Nanoparticles Induced Potent B- and T-Cell Responses Associated with Protection Against SARS-CoV-2 Infection and COVID-19-like Symptoms in Hamsters.

Vaccines (Basel). 2025 Jan 8;13(1):47. doi: 10.3390/vaccines13010047.

Antigen Delivery Platforms for Next-Generation Coronavirus Vaccines.

Vaccines (Basel). 2024 Dec 31;13(1):30. doi: 10.3390/vaccines13010030.

mRNA Vaccination: An Outlook on Innate Sensing and Adaptive Immune Responses.

Viruses. 2024 Sep 1;16(9):1404. doi: 10.3390/v16091404.

Lipid Nanoparticle-Based Delivery System-A Competing Place for mRNA Vaccines.

ACS Omega. 2024 Jan 30;9(6):6219-6234. doi: 10.1021/acsomega.3c08353. eCollection 2024 Feb 13.

mRNA-Based Nanomedicine: A New Strategy for Treating Infectious Diseases and Beyond.

Eur J Drug Metab Pharmacokinet. 2023 Sep;48(5):515-529. doi: 10.1007/s13318-023-00849-1. Epub 2023 Sep 1.

COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective.

J Intensive Med. 2021 May 18;1(1):4-13. doi: 10.1016/j.jointm.2021.04.003. eCollection 2021 Jul.

Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design.

NPJ Vaccines. 2023 Mar 8;8(1):34. doi: 10.1038/s41541-023-00613-1.

Low Resource Integrated Platform for Production and Analysis of Capped mRNA.

ACS Synth Biol. 2023 Jan 20;12(1):329-339. doi: 10.1021/acssynbio.2c00609. Epub 2022 Dec 10.

SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria.

JAMA Netw Open. 2022 Oct 3;5(10):e2236053. doi: 10.1001/jamanetworkopen.2022.36053.

Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments.

Chem Rev. 2022 Oct 26;122(20):15603-15671. doi: 10.1021/acs.chemrev.1c01032. Epub 2022 Sep 29.

本文引用的文献

Increased PIP3 activity blocks nanoparticle mRNA delivery.

Sci Adv. 2020 Jul 22;6(30):eaba5672. doi: 10.1126/sciadv.aba5672. eCollection 2020 Jul.

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.

Lancet. 2020 Aug 15;396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. Epub 2020 Jul 20.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20.

COVID-19 vaccine development and a potential nanomaterial path forward.

Nat Nanotechnol. 2020 Aug;15(8):646-655. doi: 10.1038/s41565-020-0737-y. Epub 2020 Jul 15.

COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds.

J Virol. 2020 Aug 17;94(17). doi: 10.1128/JVI.01083-20.

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.

Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22.

A strategic approach to COVID-19 vaccine R&D.

Science. 2020 May 29;368(6494):948-950. doi: 10.1126/science.abc5312. Epub 2020 May 11.

Mild Innate Immune Activation Overrides Efficient Nanoparticle-Mediated RNA Delivery.

Adv Mater. 2020 Jan;32(1):e1904905. doi: 10.1002/adma.201904905. Epub 2019 Nov 19.

Boosting Intracellular Delivery of Lipid Nanoparticle-Encapsulated mRNA.

Nano Lett. 2017 Sep 13;17(9):5711-5718. doi: 10.1021/acs.nanolett.7b02664. Epub 2017 Aug 24.

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.

Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357. doi: 10.1073/pnas.1707304114. Epub 2017 Aug 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

新冠病毒疫苗的未来如何？

Whither COVID-19 vaccines?

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献